Title:
チロシンキナーゼインヒビター組成物、並びに疾患の治療におけるそれらの製造及び使用のための方法
Document Type and Number:
Japanese Patent JP2008535795
Kind Code:
A
Abstract:
The invention is the method of using the soluble modified receptor erbB3 to treat breast cancer by competitively inhibiting ligands, such as heregulin, from binding to erbB3 tyrosine kinase receptors on cell surfaces.
Inventors:
Sara S. Bacchus
Jason E Hill
Jason E Hill
Application Number:
JP2008500820A
Publication Date:
September 04, 2008
Filing Date:
March 06, 2006
Export Citation:
Assignee:
Targeted Molecular Diagnostics LRC
International Classes:
C07K14/705; C12N5/10; C12N15/09
Attorney, Agent or Firm:
Masatake Shiga
Takashi Watanabe
Yasuhiko Murayama
Shinya Mitsuhiro
Takashi Watanabe
Yasuhiko Murayama
Shinya Mitsuhiro